OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
February 09, 2024
The three non-commercial developers of ATMPs will benefit from enhanced support from the agency.
Webinar Date/Time: Wed, Mar 13, 2024 11:00 AM EDT
February 03, 2024
Technical, regulatory, and personnel considerations characterize pharmaceutical compounding.
February 02, 2024
Agilent Technologies and Incyte have signed an agreement to collaborate on the development of companion diagnostics programs.
February 01, 2024
With the formation of the new R&D unit, Regeneron will assume full development and commercialization rights to 2seventy bio’s preclinical- and clinical-stage cell therapy pipeline.
The final guidance provides specific recommendations for CMC, pharmacology, toxicology, and clinical study design for CAR-T cell products.
January 31, 2024
In this exclusive Drug Digest video interview, Felicity Thomas, Europe/senior editor, Pharmaceutical Technology Group, interviews an esteemed panel of experts from IPEC Americas about excipient grades.
January 26, 2024
The annual industry report of the Pharmapack Europe event suggests there will be significant innovation in inhaled pulmonary and intranasal drug delivery in 2024.
January 25, 2024
The 2024 Pharmapack Europe Award winners include companies involved in ground-breaking innovations in novel drug delivery solutions, reusable connected devices, and recyclable packaging.